News | July 26, 2023
Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
There is a pressing need for continuous improvement and innovation in food safety systems to keep pace with emerging food trends and habits
Health-tech startups have the potential to revolutionize the healthcare sector by supporting innovations
1. 10 crore teleconsultations have been rendered to senior citizens and 5,22,15,224 to women
This product would be manufactured at Lupin's Nagpur facility in India
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
This transformation will enable GE HealthCare to build a strong foundation for business growth
Subscribe To Our Newsletter & Stay Updated
